Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Tom Genna who wrote (1174)	11/23/1998 11:06:00 PM
From: MJ	Read Replies (2) \| Respond to of 1510

Tom Genna ARAVA is good news. However, I am hopeful that there will be something more than another drug to stem the symptoms. The most important aspect of ARAVA is the claim that ARAVA is the only drug known to stem the deteriorating effects of RA on joints. I believe the cause of RA is where IMNR should look----genetic, viral, bacterial----a combination. The cause can then be addressed via gene manipulation or vacine. Not the disease after it begins. mj